Cyclerion Therapeutics

KRSA · NASDAQ

$31.03−$0.38 (−1.21%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $31.41

About KRSA

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Employees: 1
Headquarters: Cambridge, Massachusetts
Listed: Mar 18, 2019
Sector: Health Care
Industry: Biotechnology
Website: cyclerion.com

Leadership

Cyclerion Therapeutics executives
Name	Title	Since	Age
Errol De Souza	—	—	71
Regina Graul	—	2023	48
Rhonda Chicko	—	—	59
Peter Hecht	—	2019	61
Michael Higgins	—	—	62
Steven Hyman	—	—	72
Dina Katabi	—	—	53

Similar companies

Companies in the same industry as Cyclerion Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.